Paclitaxel plus carboplatin versus paclitaxel plus epirubicin as first-line treatment for metastatic breast cancer: Efficacy and safety results of a randomized, phase III trial.-MedSci.cn

Paclitaxel plus carboplatin versus paclitaxel plus epirubicin as first-line treatment for metastatic breast cancer: Efficacy and safety results of a randomized, phase III trial.

Tong, ZS; Li, SF; Shi, YH; Wang, X; Wang, C; Hao, CF; Wang, XR; Meng, WJ; Zhang, L

JOURNAL OF CLINICAL ONCOLOGY, 2017; 35 ( ):

科室
- - 订阅+
  - 更多科室
工具
服务